Review
Oncology
Parnaz Merikhian, Mohammad Reza Eisavand, Leila Farahmand
Summary: Triple-negative breast cancer presents challenges in treatment strategies due to its complexity and heterogeneity, with research showing the pivotal role of Wnt/beta-catenin signaling in resistance development.
CANCER CELL INTERNATIONAL
(2021)
Article
Pharmacology & Pharmacy
Zedong Cai, Meng-Lei Huan, Yao-Wen Zhang, Ting-Ting Zhao, Tian-Yan Han, Wei He, Si-Yuan Zhou, Bang-Le Zhang
Summary: Breast cancer is the most common malignant tumor, particularly drug resistant triple negative breast cancer (TNBC). A combination therapeutic system using dopamine and tumor targeted folic acid modified dopamine as carrier materials was constructed in this study. The optimized nanoparticles exhibited efficient loading of camptothecin and iron, tumor targeted delivery ability, pH-sensitive controlled release, effective photothermal conversion performance, and excellent anti-tumor efficacy in vitro and in vivo. The strategy of CPT/Fe@PDA-FA10 plus laser treatment provided a promising approach for the effective treatment of drug resistant TNBC.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Pharmacology & Pharmacy
Moon Jung Choi, Yeon Kyung Lee, Kang Chan Choi, Do Hyun Lee, Hwa Yeon Jeong, Seong Jae Kang, Min Woo Kim, Young Myoung You, Chan Su Im, Tae Sup Lee, Yong Serk Park
Summary: Biocompatible theranostic erythrocyte-derived nanoparticles (EDNs) were developed for effective early diagnosis and treatment of triple-negative breast cancer (TNBC). The EDNs encapsulated the anti-cancer drug doxorubicin (DOX) and incorporated diagnostic quantum dots (QDs) for tumor bio-imaging. The surface of the EDNs was conjugated with anti-epidermal growth factor receptor (EGFR) antibody molecules to achieve TNBC targeting. This study demonstrated that the resulting antibody-conjugated EDNs exhibited strong biocompatibility, prolonged blood circulation, and efficient targeting of TNBC, making them potential co-delivery systems for therapeutics and diagnostics.
Article
Biochemistry & Molecular Biology
Longkun Wang, Chunqian Zhao, Lu Lu, Honglei Jiang, Fengshan Wang, Xinke Zhang
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis, and the current treatment mainly relies on surgery and chemotherapy. However, the application of paclitaxel (PTX) is limited due to its hydrophobicity and side effects. To overcome these problems, a novel PTX conjugate called PTX-SM-TAR was constructed, which improved the specificity and penetrability of PTX at the tumor site. PTX-SM-TAR exhibited receptor-targeting and endocytosis-mediated cell uptake, as well as great transvascular transport and tumor penetration ability. In vivo experiments showed that PTX-SM-TAR had higher antitumor effects compared to PTX, suggesting its potential as a targeted delivery system for TNBC treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Engineering, Biomedical
Lu Lu, Genhua Liu, Chuanchuan Lin, Ke Li, Tingting He, Jixi Zhang, Zhong Luo, Kaiyong Cai
Summary: The study introduces a novel nanocarrier for breast cancer treatment that targets both tumors and mitochondria, demonstrating great potential in enhancing the efficacy of cancer therapy.
ADVANCED HEALTHCARE MATERIALS
(2021)
Review
Oncology
Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
Summary: TNBC, characterized by absence of ER, PR, and HER2 expression, is a highly aggressive subtype of breast cancer. Conventional chemotherapy remains the main treatment, but the lack of targeted therapies has led to exploration of PARP inhibitors and immune checkpoint inhibitors as potential options. Other agents targeting various pathways are also under investigation.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Abygail G. Chapdelaine, Gongqin Sun
Summary: Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 receptor. Developing targeted therapies for TNBC has been a major challenge due to its heterogeneity, and its treatment still largely relies on surgery, radiation therapy, and chemotherapy. Accumulating evidence supports TNBCs as multi-driver cancers, and a strategy designed to generate mechanism-based combination targeted therapies for TNBC is discussed.
Review
Biochemistry & Molecular Biology
Linlin Lu, Zihe Niu, Zhujun Chao, Cuiping Fu, Kai Chen, Yaqin Shi
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and standard treatment options are limited. Antibody-drug conjugates (ADCs) have shown promise in clinical studies, but resistance is a challenge. Combining ADCs with other treatment strategies may provide a more effective approach.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Review
Oncology
Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Summary: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, lacks expression of estrogen receptor, progesterone receptor, and HER2. Although chemotherapy is the main treatment for TNBC, its effectiveness is limited. Various targeted therapies, including inhibitors of the PI3K/AKT/mTOR pathway, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates, have emerged. Additionally, immune checkpoint inhibitors such as pembrolizumab, atezolizumab, and durvalumab, are being extensively investigated. This review summarizes recent advances in targeted therapy and immunotherapy in TNBC, aiming to serve as a reference for future development of personalized treatment for TNBC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Immunology
Yingnan Si, Ya Zhang, Jia-Shiung Guan, Hanh Giai Ngo, Angela Totoro, Ajeet Pal Singh, Kai Chen, Yuanxin Xu, Eddy S. Yang, Lufang Zhou, Runhua Liu, Xiaoguang (Margaret) Liu
Summary: Targeting CD47 with a monoclonal antibody shows great potential in treating TNBC with high specificity. The antibody-drug conjugate demonstrated higher potency in TNBC cells compared to free drugs and significantly inhibited tumor growth. Whole blood analysis indicated no general immune toxicity of the anti-CD47 mAb.
Article
Multidisciplinary Sciences
Jiawen Bu, Yixiao Zhang, Sijin Wu, Haonan Li, Lisha Sun, Yang Liu, Xudong Zhu, Xinbo Qiao, Qingtian Ma, Chao Liu, Nan Niu, Jinqi Xue, Guanglei Chen, Yongliang Yang, Caigang Liu
Summary: The KK-LC-1-FAT1-Hippo-ALDH1A1 pathway is identified as a therapeutic target in ALDH(+) cells of TNBC. The small-molecule inhibitor Z839878730 (Z8) can disrupt KK-LC-1 and FAT1 binding, reactivates the Hippo pathway, and suppresses TNBC tumor growth.
NATURE COMMUNICATIONS
(2023)
Article
Pharmacology & Pharmacy
Zimiao Luo, Sunyi Wu, Jianfen Zhou, Weixia Xu, Qianzhu Xu, Linwei Lu, Cao Xie, Yu Liu, Weiyue Lu
Summary: Brain metastasis is a common and serious complication of breast cancer, especially in triple-negative breast cancer (TNBC). This study develops a Y-shaped peptide pVAP-decorated platelet-hybrid liposome drug delivery system to achieve targeted drug delivery for the treatment of brain metastasis from TNBC. The results show that this delivery platform significantly improves drug accumulation and exhibits superior inhibition of brain metastasis compared to the free drug. This work provides a promising prospect for the comprehensive treatment of brain metastasis in TNBC.
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Biochemistry & Molecular Biology
Cristina J. Dias, Luisa Helguero, Maria Amparo F. Faustino
Summary: This article reviews the latest developments in targeted therapy for triple-negative breast cancer using chlorin-based photoactive molecules. Photodynamic therapy, whether used alone or in combination with other therapies such as chemotherapy or photothermal therapy, has the potential to be a safe and promising approach against TNBC.
Review
Plant Sciences
Laleh Arzi, Homa Mollaei, Reyhane Hoshyar
Summary: This review provides an unprecedented overview of the use of plants and herbal derivatives to inhibit the progression of TNBC by targeting the Wnt/beta-catenin pathway. Herbal medicine extracts and bioactive compounds have been shown to interrupt various steps of Wnt/beta-catenin signaling and inhibit proliferation, metastasis, self-renewal of breast cancer stem cells, and induce apoptosis in TNBC models. These herbal remedies also have the potential to target other overactive pathways in TNBC. Overall, the repression of the Wnt/beta-catenin signaling pathway by herbal derivatives plays an important role in the treatment of TNBC.
Article
Oncology
Ghazal Nabil, Rami Alzhrani, Hashem O. Alsaab, Mohammed Atef, Samaresh Sau, Arun K. Iyer, Hossny El Banna
Summary: Triple-negative breast cancer (TNBC) is a challenging and aggressive tumor with limited therapeutic options. Combination therapies, such as using apoptosis inducers and JAK/STAT3 inhibitors, have shown improvement in TNBC cell killing activity. CD44 targeted polymeric nanoparticles and Hyaluronic acid-tagged nanoparticles have enhanced drug activity and tumor accumulation, leading to improved therapeutic efficacy for TNBC treatment.
Review
Pharmacology & Pharmacy
Yonika Larasati, Cedric Boudou, Alexey Koval, Vladimir L. Katanaev
Summary: The Wnt signaling pathway plays a critical role in carcinogenesis, and FZD(7) receptor is important in various cancers. This review summarises the functions of FZD(7) in carcinogenesis and tissue homeostasis, discusses the development of drugs targeting FZD(7), and explores the challenges and possibilities in developing FZD(7)-selective antagonists.
DRUG DISCOVERY TODAY
(2022)
Article
Multidisciplinary Sciences
Cezanne Miete, Gonzalo P. Solis, Alexey Koval, Martina Bruckner, Vladimir L. Katanaev, Jurgen Behrens, Dominic B. Bernkopf
Summary: This study finds that G alpha i2 can induce the condensation of conductin, leading to the degradation of β-catenin and inhibition of Wnt signaling, thus suppressing the growth of colorectal cancer. Colorectal cancer evades this inhibition by decreasing the expression of G alpha i2 and inactivating mutations, but the G alpha i2-activating drug guanabenz can reduce colorectal cancer growth.
NATURE COMMUNICATIONS
(2022)
Article
Plant Sciences
Robin Huber, Laurence Marcourt, Alexey Koval, Sylvain Schnee, Davide Righi, Emilie Michellod, Vladimir L. Katanaev, Jean-Luc Wolfender, Katia Gindro, Emerson Ferreira Queiroz
Summary: A series of complex phenylpropanoid derivatives were obtained by chemoenzymatic biotransformation. These compounds showed anti-Wnt activity and have potential applications.
FRONTIERS IN PLANT SCIENCE
(2022)
Article
Neurosciences
Denis Silachev, Alexey Koval, Mikhail Savitsky, Guru Padmasola, Charles Quairiaux, Fabrizio Thorel, Vladimir L. Katanaev
Summary: This study establishes two mouse models of GNAO1 encephalopathy, which simulate different clinical manifestations of the disease and reveal it as a neurodevelopmental disorder. These models contribute to understanding the disease mechanism and developing future treatment approaches.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Antonina Klimenko, Robin Huber, Laurence Marcourt, Dmitry Tabakaev, Alexey Koval, Salim Sh. Dautov, Tatyana N. N. Dautova, Jean-Luc Wolfender, Rob Thew, Yuri Khotimchenko, Emerson Ferreira Queiroz, Vladimir L. L. Katanaev
Summary: Through metabolite analysis, we have identified five new chlorin compounds from Ophiura sarsii and O. ooplax, demonstrating their potential applications in photodynamic therapy.
Review
Biochemistry & Molecular Biology
Vladimir L. Katanaev, Alexey Baldin, Tatiana V. Denisenko, Denis N. Silachev, Anna E. Ivanova, Gennadiy T. Sukhikh, Lee Jia, Lev A. Ashrafyan
Summary: Wnt signaling plays multiple important roles in cancer, including primary transformation, tumor growth, and metastasis. It is not only crucial for cancer cell-intrinsic functions but also for cross-communication among different cell types in the tumor microenvironment. Various cell types, such as fibroblasts, macrophages, endothelial cells, and lymphocytes, use the Wnt language to communicate with cancer cells and each other, and these messages are essential for tumor progression and fate. Decoding this language will provide valuable insights into tumor biology and lead to novel therapeutic strategies.
TRENDS IN MOLECULAR MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Vladimir L. Katanaev
Summary: Neuroscience and neurology research heavily relies on experimentation with rodents, but non-vertebrate models such as fruit flies have not been able to fully replace mice and rats in these studies. One reason is that existing methodologies for creating fruit fly models of neurological diseases do not accurately reflect the genetic conditions of the diseases. Therefore, the author argues for a systematic humanization approach, where the fruit fly orthologs of human disease genes are replaced with the human sequences. This approach would improve disease modeling and drug discovery in fruit flies.
ANIMAL MODELS AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Alexey Koval, Yonika A. Larasati, Mikhail Savitsky, Gonzalo P. Solis, Jean-Marc Good, Mathieu Quinodoz, Carlo Rivolta, Andrea Superti-Furga, Vladimir L. Katanaev
Summary: A study found a mutation in the GNAO1 gene associated with pediatric encephalopathies. A precision medicine workflow combining NGS diagnostics, molecular etiology analysis, and personalized drug discovery was used to study this mutation. The mutation was found to cause structural changes in the Gao protein, leading to aberrant biochemical functions and providing insights into the molecular etiology of this pathology.
Article
Microbiology
Alexey Koval, Jiabin Xu, Nathalia Williams, Mirco Schmolke, Karl-Heinz Krause, Vladimir L. Katanaev
Summary: Despite previous indications, pharmacological modulation of the Wnt pathway is not a promising strategy to control SARS-CoV-2 infection in lung epithelia.
MICROBIOLOGY SPECTRUM
(2023)
Article
Multidisciplinary Sciences
Alexey Koval, Xin Zhang, Vladimir L. Katanaev
Summary: Intracellular signaling plays crucial roles in an organism's development and functioning, and dysregulation of signaling pathways can lead to various pathologies, including cancer. A key characteristic of cell signaling is channel capacity, which measures how much information can be reliably transmitted by a signaling system. In this study, we present improved methods to quantify the channel capacity of GPCR signaling in single cells, and we analyze the channel capacity of cancer cells for the first time. We find that different types of cancer cells exhibit decreased channel capacity in their GPCR signaling, supporting the hypothesis that cancer is an information disease. These findings have important implications for understanding cancer biology and discovering new anticancer drugs.
Meeting Abstract
Plant Sciences
R. Huber, L. Marcourt, A. Luscher, A. Koval, N. Hanna, J. Nitschke, S. Schnee, E. Michellod, T. Kohler, V. L. Katanaev, T. Soldati, J-L Wolfender, K. Gindro, Queiroz E. Ferreira
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.
